NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

ATLnsider I appreciate dearly you putting your DD into a very vivid table for any ones to see how the primary endpoint will be readily met, and in general your valuable contribution.

Just like you to ponder meeting all the endpoints may not be a super good thing. For example, if DCVax-L is indeed very effective, it may bring about a very strong immunogenic reaction, i.e., there may have been indeed lots of pseudoprogression.

As a result, the third secondary endpoint, "The third secondary endpoint, PFS, is progression-free survival compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221," may not be met or should not be met without adjudication.

There may also be other interwoven, interactive, somewhat conflicting effects as well, not really necessary meaning it will be a super good thing to have all endpoints met.

Simply put, there are many combinations to show DCVax-L is indeed both very safe and effective vaccine.

This is my last post for today. GLTA long!